Literature DB >> 6488592

Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen.

A M Carroll, M Zalutsky, S Schatten, A Bhan, L L Perry, C Sobotka, B Benacerraf, M I Greene.   

Abstract

Monoclonal antibodies were raised to PC-3 human prostate adenocarcinoma cells, and one hybridoma, designated F77-129, was extensively purified and used to characterize a PC-3 antigen. The F77-129 antibody also showed serological reactivity with the Du-145 prostate cancer line and with three of four breast carcinoma lines tested; it showed variable binding to a colon carcinoma line. Several other lines tested, including melanomas, fibrosarcomas, and leukemias, were completely negative. Immunoperoxidase staining of frozen surgical specimens showed binding to both normal and malignant prostate and breast tissue. Injection of radioiodinated F77-129 into tumor-bearing nude mice showed specific in vivo targeting to prostatic cancer implants. The antigen also showed surface modulation by bound antibody, suggesting possible clinical utility of this antibody in delivering immunotoxins to tumors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488592     DOI: 10.1016/0090-1229(84)90081-3

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  9 in total

Review 1.  The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities.

Authors:  Huiyuan Tang; Peter Hsueh; Doron Kletter; Marshall Bern; Brian Haab
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 2.  Anti-idiotypic antibodies as probes of cell surface receptors.

Authors:  G N Gaulton; M S Co; H D Royer; M I Greene
Journal:  Mol Cell Biochem       Date:  1984-11       Impact factor: 3.396

3.  Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker.

Authors:  Geng Zhang; Hongtao Zhang; Qiang Wang; Priti Lal; Ann M Carroll; Margarita de la Llera-Moya; Xiaowei Xu; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-18       Impact factor: 11.205

4.  Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array.

Authors:  Chao Gao; Yan Liu; Hongtao Zhang; Yibing Zhang; Michiko N Fukuda; Angelina S Palma; Radoslaw P Kozak; Robert A Childs; Motohiro Nonaka; Zhen Li; Don L Siegel; Peter Hanfland; Donna M Peehl; Wengang Chai; Mark I Greene; Ten Feizi
Journal:  J Biol Chem       Date:  2014-04-21       Impact factor: 5.157

5.  Determination of carbohydrate structure recognized by prostate-specific F77 monoclonal antibody through expression analysis of glycosyltransferase genes.

Authors:  Motohiro Nonaka; Michiko N Fukuda; Chao Gao; Zhen Li; Hongtao Zhang; Mark I Greene; Donna M Peehl; Ten Feizi; Minoru Fukuda
Journal:  J Biol Chem       Date:  2014-04-21       Impact factor: 5.157

6.  A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77.

Authors:  Xi Chen; Yasuhiro Nagai; Zhiqiang Zhu; Hang Ruan; Donna M Peehl; Mark I Greene; Hongtao Zhang
Journal:  Oncotarget       Date:  2017-12-16

Review 7.  The role of glycans in the development and progression of prostate cancer.

Authors:  Jennifer Munkley; Ian G Mills; David J Elliott
Journal:  Nat Rev Urol       Date:  2016-04-19       Impact factor: 14.432

8.  I-branching N-acetylglucosaminyltransferase regulates prostate cancer invasiveness by enhancing α5β1 integrin signaling.

Authors:  Jotaro Mikami; Yuki Tobisawa; Tohru Yoneyama; Shingo Hatakeyama; Kazuyuki Mori; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama; Minoru Fukuda
Journal:  Cancer Sci       Date:  2016-02-10       Impact factor: 6.716

9.  Shotgun Glycomics Identifies Tumor-Associated Glycan Ligands Bound by an Ovarian Carcinoma-Specific Monoclonal Antibody.

Authors:  B Liau; B Tan; G Teo; P Zhang; A Choo; P M Rudd
Journal:  Sci Rep       Date:  2017-11-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.